Related Experiment Videos
Glucosylceramide: a marker for multiple-drug resistant cancers
1Division of Surgical Oncology, Saint John's Health Center, Santa Monica, CA 90404, USA.
Anticancer Research
|May 6, 1998
Summary
Glucosylceramide is a novel marker for identifying multiple-drug resistance (MDR) in cancer. Its presence indicates tumors resistant to chemotherapy, aiding early detection and treatment strategies.
Area of Science:
- Biochemistry
- Oncology
- Cancer Research
Background:
- Multiple-drug resistance (MDR) significantly contributes to chemotherapy failure.
- Identifying reliable biomarkers for MDR is crucial for effective cancer treatment.
Purpose of the Study:
- To investigate glucosylceramide as a potential biomarker for MDR in human cancer cells and patient tumors.
- To evaluate the clinical significance of glucosylceramide in predicting chemotherapy response.
Main Methods:
- Lipid analysis of human MDR cancer cell lines and their drug-sensitive counterparts.
- Quantification of glucosylceramide in melanoma and breast tumor specimens using mass spectrometry and radiolabeled precursor utilization.
- Thin-layer chromatography for lipid component resolution.
Main Results:
- Glucosylceramide was consistently detected in MDR cell lines but absent or at very low levels in drug-sensitive cells.
- The marker was present in all patients who experienced chemotherapy failure and absent in those who responded to treatment.
- Patient follow-up ranged from 8 to 22 months.
Conclusions:
- Glucosylceramide shows promise as a clinical marker for early identification of drug-resistant tumors.
- This finding could lead to improved diagnostic tools for personalized cancer therapy.